

## **Ziextenzo** <sup>[1]</sup>

### **PrZiextenzo<sup>®</sup>**

Ziextenzo<sup>®</sup> (pegfilgrastim injection) is a biologic drug (biosimilar) to Neulasta<sup>®</sup>.

Ziextenzo<sup>®</sup> is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drugs.

Ziextenzo<sup>®</sup> is the third Sandoz biosimilar available in Canada.

Click [here](#) <sup>[2]</sup> to consult the product monograph of Ziextenzo<sup>®</sup>

\* Ziextenzo<sup>®</sup> is a registered trademark owned or used under license by Sandoz Canada Inc.

\*\* Neulasta<sup>®</sup> is a registered trademark of Amgen in Canada.

#### **Publish Date:**

May 06, 2020

#### **Accordion Type:**

Collapsible

---

**Source URL:** <https://www.sandoz.ca/en/products/patients/biosimilars/ziextenzo2>

#### **Links**

[1] <https://www.sandoz.ca/en/products/patients/biosimilars/ziextenzo2>

[2] <https://prod.sandoz.ca/sites/www.sandoz.ca/files/Ziextenzo%20Product%20Monograph.pdf>